338 related articles for article (PubMed ID: 25339352)
1. Oncogenic KRAS confers chemoresistance by upregulating NRF2.
Tao S; Wang S; Moghaddam SJ; Ooi A; Chapman E; Wong PK; Zhang DD
Cancer Res; 2014 Dec; 74(24):7430-41. PubMed ID: 25339352
[TBL] [Abstract][Full Text] [Related]
2. Oncogenic KRAS mutation confers chemoresistance by upregulating SIRT1 in non-small cell lung cancer.
Shin DH; Jo JY; Choi M; Kim KH; Bae YK; Kim SS
Exp Mol Med; 2023 Oct; 55(10):2220-2237. PubMed ID: 37779142
[TBL] [Abstract][Full Text] [Related]
3. Brusatol attenuated proliferation and invasion induced by KRAS in differentiated thyroid cancer through inhibiting Nrf2.
Gong Z; Xue L; Vlantis AC; van Hasselt CA; Chan JYK; Fang J; Wang R; Yang Y; Li D; Zeng X; Tong MCF; Chen GG
J Endocrinol Invest; 2024 May; 47(5):1271-1280. PubMed ID: 38062319
[TBL] [Abstract][Full Text] [Related]
4. Brusatol provokes a rapid and transient inhibition of Nrf2 signaling and sensitizes mammalian cells to chemical toxicity-implications for therapeutic targeting of Nrf2.
Olayanju A; Copple IM; Bryan HK; Edge GT; Sison RL; Wong MW; Lai ZQ; Lin ZX; Dunn K; Sanderson CM; Alghanem AF; Cross MJ; Ellis EC; Ingelman-Sundberg M; Malik HZ; Kitteringham NR; Goldring CE; Park BK
Free Radic Biol Med; 2015 Jan; 78():202-12. PubMed ID: 25445704
[TBL] [Abstract][Full Text] [Related]
5. RAGE is essential for oncogenic KRAS-mediated hypoxic signaling in pancreatic cancer.
Kang R; Hou W; Zhang Q; Chen R; Lee YJ; Bartlett DL; Lotze MT; Tang D; Zeh HJ
Cell Death Dis; 2014 Oct; 5(10):e1480. PubMed ID: 25341034
[TBL] [Abstract][Full Text] [Related]
6. The mutational landscapes of genetic and chemical models of Kras-driven lung cancer.
Westcott PM; Halliwill KD; To MD; Rashid M; Rust AG; Keane TM; Delrosario R; Jen KY; Gurley KE; Kemp CJ; Fredlund E; Quigley DA; Adams DJ; Balmain A
Nature; 2015 Jan; 517(7535):489-92. PubMed ID: 25363767
[TBL] [Abstract][Full Text] [Related]
7. BYL719, a selective inhibitor of phosphoinositide 3-Kinase α, enhances the effect of selumetinib (AZD6244, ARRY-142886) in KRAS-mutant non-small cell lung cancer.
Ku BM; Jho EH; Bae YH; Sun JM; Ahn JS; Park K; Ahn MJ
Invest New Drugs; 2015 Feb; 33(1):12-21. PubMed ID: 25342139
[TBL] [Abstract][Full Text] [Related]
8. Mutant p53 confers chemoresistance in non-small cell lung cancer by upregulating Nrf2.
Tung MC; Lin PL; Wang YC; He TY; Lee MC; Yeh SD; Chen CY; Lee H
Oncotarget; 2015 Dec; 6(39):41692-705. PubMed ID: 26497680
[TBL] [Abstract][Full Text] [Related]
9. NRF2 Pathway Activation and Adjuvant Chemotherapy Benefit in Lung Squamous Cell Carcinoma.
Cescon DW; She D; Sakashita S; Zhu CQ; Pintilie M; Shepherd FA; Tsao MS
Clin Cancer Res; 2015 Jun; 21(11):2499-505. PubMed ID: 25739673
[TBL] [Abstract][Full Text] [Related]
10. Dual roles of NRF2 in tumor prevention and progression: possible implications in cancer treatment.
Moon EJ; Giaccia A
Free Radic Biol Med; 2015 Feb; 79():292-9. PubMed ID: 25458917
[TBL] [Abstract][Full Text] [Related]
11. Decreased tumorigenesis in mice with a Kras point mutation at C118.
Huang L; Carney J; Cardona DM; Counter CM
Nat Commun; 2014 Nov; 5():5410. PubMed ID: 25394415
[TBL] [Abstract][Full Text] [Related]
12. The emerging role of Nrf2 in mitochondrial function.
Dinkova-Kostova AT; Abramov AY
Free Radic Biol Med; 2015 Nov; 88(Pt B):179-188. PubMed ID: 25975984
[TBL] [Abstract][Full Text] [Related]
13. Genetic polymorphism in the NRF2 gene as a prognosis marker for cancer chemotherapy.
Ishikawa T
Front Genet; 2014; 5():383. PubMed ID: 25408701
[TBL] [Abstract][Full Text] [Related]
14. A Curcumin Derivative That Inhibits Vinyl Carbamate-Induced Lung Carcinogenesis via Activation of the Nrf2 Protective Response.
Shen T; Jiang T; Long M; Chen J; Ren DM; Wong PK; Chapman E; Zhou B; Zhang DD
Antioxid Redox Signal; 2015 Sep; 23(8):651-64. PubMed ID: 25891177
[TBL] [Abstract][Full Text] [Related]
15. Molecular mechanisms of Nrf2 regulation and how these influence chemical modulation for disease intervention.
Harder B; Jiang T; Wu T; Tao S; Rojo de la Vega M; Tian W; Chapman E; Zhang DD
Biochem Soc Trans; 2015 Aug; 43(4):680-6. PubMed ID: 26551712
[TBL] [Abstract][Full Text] [Related]
16. Structural and functional characterization of Nrf2 degradation by glycogen synthase kinase 3/β-TrCP.
Cuadrado A
Free Radic Biol Med; 2015 Nov; 88(Pt B):147-157. PubMed ID: 25937177
[TBL] [Abstract][Full Text] [Related]
17. Clinical next-generation sequencing in patients with non-small cell lung cancer.
Hagemann IS; Devarakonda S; Lockwood CM; Spencer DH; Guebert K; Bredemeyer AJ; Al-Kateb H; Nguyen TT; Duncavage EJ; Cottrell CE; Kulkarni S; Nagarajan R; Seibert K; Baggstrom M; Waqar SN; Pfeifer JD; Morgensztern D; Govindan R
Cancer; 2015 Feb; 121(4):631-9. PubMed ID: 25345567
[TBL] [Abstract][Full Text] [Related]
18. Crosstalk between Nrf2 and Notch signaling.
Wakabayashi N; Chartoumpekis DV; Kensler TW
Free Radic Biol Med; 2015 Nov; 88(Pt B):158-167. PubMed ID: 26003520
[TBL] [Abstract][Full Text] [Related]
19. Extra-Nuclear Signaling Pathway Involved in Progesterone-Induced Up-Regulations of p21cip1 and p27kip1 in Male Rat Aortic Smooth Muscle Cells.
Wang HC; Hsu SP; Lee WS
PLoS One; 2015; 10(5):e0125903. PubMed ID: 25932965
[TBL] [Abstract][Full Text] [Related]
20. Regulation of Nrf2 signaling and longevity in naturally long-lived rodents.
Lewis KN; Wason E; Edrey YH; Kristan DM; Nevo E; Buffenstein R
Proc Natl Acad Sci U S A; 2015 Mar; 112(12):3722-7. PubMed ID: 25775529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
